VistaGen Therapeutics Company Presentation

www.vistagen.com 18 • Obligations: ƒ EverInsight (funded by CBC Group) will be responsible for development and commercialization of PH94B in the Territory • Territory: • Financial terms: ƒ $5 million upfront payment (received August 2020) ƒ Potential milestone payments up to $172 million ƒ Royalties on commercial sales EverInsight/CBC Group Collaboration Development and Commercialization of PH94B in Key Asian Markets . i . ƒ Greater China ƒ South Korea ƒ Southeast Asia